Pharmacometabolomics informs pharmacogenomics

Metabolomics

Volumn 12, Issue 7, 2016, Pages

  Neavin, Drew ^a,b   Kaddurah Daouk, Rima ^c   Weinshilboum, Richard ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metabolomics; Pharmacogenomics; Pharmacometabolomics

Indexed keywords

CITALOPRAM; ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DRUG RESPONSE; GAS CHROMATOGRAPHY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; GENOTYPING TECHNIQUE; HUMAN; MAJOR DEPRESSION; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR PATHOLOGY; PHARMACOGENOMICS; PHARMACOMETABOLOMICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84977562259     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-1066-x     Document Type: Article

References (23)

1. Cross, H. E. (1976). Population studies and the old order Amish. Nature, 262(5563), 17–20.
2. Ellero-Simatos, S., Lewis, J. P., Georgiades, A., Yerges-Armstrong, L. M., Beitelshees, A. L., Horenstein, R. B., et al. (2014). Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT: Pharmacometrics and Systems Pharmacology, 3, e125. doi:10.1038/psp.2014.22.
3. Gavaghan McKee, C. L., Wilson, I. D., & Nicholson, J. K. (2006). Metabolic phenotyping of nude and normal (Alpk:ApfCD, C57BL10 J) mice. Journal of Proteome Research, 5(2), 378–384. doi:10.1021/pr050255h.
4. Gieger, C., Geistlinger, L., Altmaier, E., Hrabe de Angelis, M., Kronenberg, F., Meitinger, T., et al. (2008). Genetics meets metabolomics: A genome-wide association study of metabolite profiles in human serum. PLoS Genetics, 4(11), e1000282. doi:10.1371/journal.pgen.1000282.
5. Gupta, M., Neavin, D., Liu, D., Biernacka, J., Hall-Flavin, D., Bobo, W. V., et al. (2016). TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: Pharmacometabolomics-informed pharmacogenomics. Molecular Psychiatry. doi:10.1038/mp.2016.6.
6. Illig, T., Gieger, C., Zhai, G., Romisch-Margl, W., Wang-Sattler, R., Prehn, C., et al. (2010). A genome-wide perspective of genetic variation in human metabolism. Nature Genetics, 42(2), 137–141. doi:10.1038/ng.507.
7. Ingle, J. N., Liu, M., Wickerham, D. L., Schaid, D. J., Wang, L., Mushiroda, T., et al. (2013). Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: Individualized breast cancer prevention. Cancer Discovery, 3(7), 812–825. doi:10.1158/2159-8290.cd-13-0038.
8. Ingle, J. N., Schaid, D. J., Goss, P. E., Liu, M., Mushiroda, T., Chapman, J. A., et al. (2010). Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. Journal of Clinical Oncology, 28(31), 4674–4682. doi:10.1200/jco.2010.28.5064.
9. Jacobsen, J. P., Plenge, P., Sachs, B. D., Pehrson, A. L., Cajina, M., Du, Y., et al. (2014). The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse. Psychopharmacology (Berl), 231(23), 4527–4540. doi:10.1007/s00213-014-3595-1.
10. Ji, Y., Biernacka, J. M., Hebbring, S., Chai, Y., Jenkins, G. D., Batzler, A., et al. (2013). Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: Genome-wide associations and functional genomics. The pharmacogenomics Journal, 13(5), 456–463. doi:10.1038/tpj.2012.32.
11. Ji, Y., Hebbring, S., Zhu, H., Jenkins, G. D., Biernacka, J., Snyder, K., et al. (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics, 89(1), 97–104. doi:10.1038/clpt.2010.250.
12. Ji, Y., Schaid, D. J., Desta, Z., Kubo, M., Batzler, A. J., Snyder, K., et al. (2014). Citalopram and escitalopram plasma drug and metabolite concentrations: Genome-wide associations. British Journal of Clinical Pharmacology, 78(2), 373–383. doi:10.1111/bcp.12348.
13. Kaddurah-Daouk, R., Kristal, B. S., & Weinshilboum, R. M. (2008). Metabolomics: A global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxicology, 48, 653–683. doi:10.1146/annurev.pharmtox.48.113006.094715.
14. Kaddurah-Daouk, R., & Weinshilboum, R. M. (2014). Pharmacometabolomics: Implications for clinical pharmacology and systems pharmacology. Clinical Pharmacology and Therapeutics, 95(2), 154–167. doi:10.1038/clpt.2013.217.
15. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409(6822), 860–921. doi:10.1038/35057062.
16. Lewis, J. P., Yerges-Armstrong, L. M., Ellero-Simatos, S., Georgiades, A., Kaddurah-Daouk, R., & Hankemeier, T. (2013). Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clinical Pharmacology and Therapeutics, 94(5), 570–573. doi:10.1038/clpt.2013.153.
17. Mitchell, B. D., McArdle, P. F., Shen, H., Rampersaud, E., Pollin, T. I., Bielak, L. F., et al. (2008). The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. American Heart Journal, 155(5), 823–828. doi:10.1016/j.ahj.2008.01.019.
18. Suhre, K., Shin, S. Y., Petersen, A. K., Mohney, R. P., Meredith, D., Wagele, B., et al. (2011). Human metabolic individuality in biomedical and pharmaceutical research. Nature, 477(7362), 54–60. doi:10.1038/nature10354.
19. Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011). Genomics and drug response. New England Journal of Medicine, 364(12), 1144–1153. doi:10.1056/NEJMra1010600.
20. Wishart, D. S. (2016). Emerging applications of metabolomics in drug discovery and precision medicine. Nature Reviews Drug Discovery. doi:10.1038/nrd.2016.32.
21. Yap, I. K., Clayton, T. A., Tang, H., Everett, J. R., Hanton, G., Provost, J. P., et al. (2006). An integrated metabonomic approach to describe temporal metabolic disregulation induced in the rat by the model hepatotoxin allyl formate. Journal of Proteome Research, 5(10), 2675–2684. doi:10.1021/pr0601584.
22. Yerges-Armstrong, L. M., Ellero-Simatos, S., Georgiades, A., Zhu, H., Lewis, J. P., Horenstein, R. B., et al. (2013). Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics, 94(4), 525–532. doi:10.1038/clpt.2013.119.
23. Zhong, H., Hansen, K. B., Boyle, N. J., Han, K., Muske, G., Huang, X., et al. (2009). An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: Kinetic binding studies with the ALI/VFL-SI/TT mutant. Neuroscience Letters, 462(3), 207–212. doi:10.1016/j.neulet.2009.07.030.